Beauty Health Co

Beauty Health Co. reported a net loss of $(2.67) million for Q2 2026, a significant reversal from the $19.71 million net income in Q2 2025, with net sales declining 7.77% to $72.11 million. Year-to-date, the company used $(2.88) million in operating cash, contrasting with $12.64 million provided in the prior year. The company also announced preliminary settlements for both a Securities Class Action and a Customer Class Action, with the former totaling $18.0 million.

SkinHealth Systems reported Q2 2026 net sales of $72.1 million, a 7.8% decrease year-over-year, and a net loss of $(2.7) million. Despite sales pressure, the company achieved an adjusted EBITDA of $17.0 million, exceeding guidance, driven by improved gross margin and disciplined operating expense management. The company also revised its full-year 2026 financial guidance downwards, reflecting continued sales pressure while maintaining cost discipline.

SkinHealth Systems Inc. announced it will release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Following the release, the company will host an investor conference call at 4:30 p.m. Eastern Time. A live webcast and supporting materials will be available on the company's investor relations website, with a recording accessible approximately three hours post-call.

SkinHealth Systems Inc. announced that its SkinStylus microneedling device has received U.S. FDA clearance for the improvement of the appearance of periorbital wrinkles in adults aged 22 and older across all Fitzpatrick skin types. This expands the device's clinically supported indications, which now include facial acne scars and abdominal scars. The company highlighted the rapid growth in the microneedling market, with consumer spend reaching $330 million in 2025, and strong interest in combining microneedling with Hydrafacial treatments.

Beauty Health Co (f/k/a SkinHealth Systems Inc.) has entered into a Stipulation and Agreement of Settlement to resolve a securities class action lawsuit. The proposed settlement, totaling $18,000,000, will see the company contribute $3,000,000, with the remaining $15,000,000 covered by its insurers. This agreement, which is subject to court approval, aims to eliminate the burden of protracted litigation, with the company denying any wrongdoing or liability.

Beauty Health Co. announced the refresh and rebranding of its Keravive scalp treatment, now called HydraScalp with Keravive . This non-invasive, in-office treatment leverages Hydrafacial's Vortex-Fusion Technology and new Purify and Nourish tips to deeply cleanse, exfoliate, and nourish the scalp. Clinical findings support its effectiveness, showing improved hair fullness, healthier-looking hair, and increased scalp hydration, addressing rising consumer demand for scalp health solutions.

Beauty Health Co. announced the termination of Ronald Menezes' employment as Chief Revenue Officer without cause, effective May 6, 2026. In connection with his departure, the company entered into a Separation Agreement on May 15, 2026. Pursuant to the agreement, Mr. Menezes will receive $463,000 in cash severance, a pro-rata 2026 annual bonus, and reimbursement for COBRA health benefit premiums. He also agreed to a release of claims and ongoing covenants, including a one-year non-solicitation clause.

Beauty Health Co (SKIN) received a notification from Nasdaq on May 8, 2026, indicating non-compliance with the Minimum Bid Price Requirement, as its Class A Common Stock traded below $1.00 for 30 consecutive business days. The company has 180 calendar days, until November 4, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. The stock will continue to trade on The Nasdaq Capital Market during this period, and the company intends to monitor its stock price and explore options to resolve the deficiency.

Beauty Health reported Q1 2026 net sales of $64.91 million, a decrease from the prior year, but significantly improved its net loss to $(6.63) million and operating loss to $(1.80) million. The company also repurchased $21.3 million of its 2026 Convertible Senior Notes, resulting in a $1.0 million gain. Updates were provided on ongoing legal proceedings, including a settlement-in-principle reached for the Customer Class Action.

SkinHealth Systems reported first-quarter 2026 financial results, with net sales of $64.9 million, a 6.7% decrease year-over-year, and a net loss of $6.6 million. Despite the revenue decline, the company significantly outperformed on adjusted EBITDA, which rose to $8.5 million from $7.3 million in Q1 2025, driven by lower operational spend. The company is lowering its full-year 2026 net sales outlook to $280-$295 million, citing continued pressure on device sales and a challenging market, while maintaining its adjusted EBITDA guidance.